Veliparib-Chemo Combo Prolongs Survival Without Disease Progression in Certain Advanced Breast Cancer Patients, Phase 3 Trial Shows

Veliparib-Chemo Combo Prolongs Survival Without Disease Progression in Certain Advanced Breast Cancer Patients, Phase 3 Trial Shows
Veliparib in combination with chemotherapy significantly prolongs survival without disease progression in women with metastatic HER2-negative breast cancer with BRCA mutations, compared with women on chemotherapy alone, a Phase 3 trial shows. The trial’s findings were presented in a session, titled "Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer," at the recent European Society for Medical Oncology (ESMO) 2019 Congress, in Barcelona. Veliparib is an experimental anti-cancer therapy that is being developed by AbbVie to treat certain forms of lung, ovarian, and breast cancer. It is a PARP inhibitor that works by blocking the activity of PARP enzymes, which are involved in DNA repair. By blocking the activity of these enzymes, veliparib prevents can
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.